-
<![CDATA[2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer]]>
13 Dec 2025 22:52 GMT
… , capecitabine, vinorelbine, or gemcitabine. Randomization was stratified by prior …
The FDA approved T-DXd for the treatment of … phase 3 DESTINY-Breast06 trial (NCT04494425), which evaluated … Regulatory Approvals, and the Trials Ahead. Presented at: SABCS …
-
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
12 Dec 2025 18:38 GMT
… cancer treatment landscape,” said Jared Kelly, CEO of Oncolytics Biotech. … The trial will test three arms: standard chemotherapy (gemcitabine plus … with the Canadian Cancer Trials Group and supported … 47;05/cancer-pancreatic-drug-fda-trump/
https:…
-
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
12 Dec 2025 18:54 GMT
… Arcus Biosciences’ Investigational Cancer Drug Shows Overall Survival Of … were optioned to Taiho Pharmaceutical in October 2025.
The … Phase 3 PRISM-1 trial in first-line metastatic … 2027, evaluating quemliclustat plus gemcitabine/nab-paclitaxel versus …
-
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
12 Dec 2025 15:31 GMT
… treatment landscape," said Jared Kelly, CEO of Oncolytics Biotech. … The trial will test three arms: standard chemotherapy (gemcitabine plus … with the Canadian Cancer Trials Group and supported by … 47;05/cancer-pancreatic-drug-fda-trump/
https:…
-
<![CDATA[Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS]]>
14 Dec 2025 16:44 GMT
… observed between the 2 treatment groups, indicating that … , PhD, MBA, chief medical officer at Cantargia, in … CANFOUR trial (NCT03267316), completed in 2024, nadunolimab combined with gemcitabine… nadunolimab antibody awarded US FDA Fast Track Designation. …
-
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
11 Dec 2025 18:37 GMT
… . Food and Drug Administration (FDA) has accepted … gemcitabine, is indicated as first-line treatment … including infection. Institute medical management promptly, including … KEYWORD: ONCOLOGY FDA HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: …
-
<![CDATA[Gal Wald, MD on PROs from phase 2 gemcitabine + BCG trial in NMIBC]]>
10 Dec 2025 17:29 GMT
… from a phase 2 trial (NCT04179162) of intravesical gemcitabine plus BCG for … ).1
Previous data from the trial were presented in 2024, showing … urology resident at Weill Cornell Medicine in New York, New York …
-
Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
10 Dec 2025 02:23 GMT
… stage biotech company focused on innovative drug discovery … gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment … University of Pittsburgh Medical Center
ABOUT SPEVATAMIG
… drug designation (ODD) for the treatment of pancreatic cancer by the FDA …
-
<![CDATA[Sacituzumab Govitecan/Pembrolizumab Offers Manageable, Predictable Safety Profile in TNBC]]>
12 Dec 2025 21:41 GMT
… pembrolizumab were highest early in treatment. Most incidences of diarrhea … chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin) until disease progression … 49% received gemcitabine/carboplatin. The median duration of treatment was 8 …
-
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
12 Dec 2025 16:56 GMT
… treatment landscape," said Jared Kelly, CEO of Oncolytics Biotech … trial will test three arms: standard chemotherapy (gemcitabine … for glioblastoma, received FDA Orphan Drug Designation for malignant … updates on Revolution Medicines'; daraxonrasib showing …
About
© 1995-2025